Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1.
HIV Res Clin Pract
; 21(6): 151-167, 2020 12.
Article
in En
| MEDLINE
| ID: mdl-33528318
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
HIV Infections
/
HIV-1
/
Anti-HIV Agents
Type of study:
Clinical_trials
Limits:
Adult
/
Humans
/
Middle aged
Language:
En
Journal:
HIV Res Clin Pract
Year:
2020
Document type:
Article
Affiliation country:
Country of publication: